Article

FKBP51 and FKBP52 in signaling and disease

The Border Biomedical Research Center and Department of Biological Sciences, University of Texas at El Paso, El Paso, TX 79968, USA.
Trends in Endocrinology and Metabolism (Impact Factor: 8.87). 08/2011; 22(12):481-90. DOI: 10.1016/j.tem.2011.08.001
Source: PubMed

ABSTRACT FKBP51 and FKBP52 are diverse regulators of steroid hormone receptor signaling, including receptor maturation, hormone binding and nuclear translocation. Although structurally similar, they are functionally divergent, which is largely attributed to differences in the FK1 domain and the proline-rich loop. FKBP51 and FKBP52 have emerged as likely contributors to a variety of hormone-dependent diseases, including stress-related diseases, immune function, reproductive functions and a variety of cancers. In addition, recent studies have implicated FKBP51 and FKBP52 in Alzheimer's disease and other protein aggregation disorders. This review summarizes our current understanding of FKBP51 and FKBP52 interactions within the receptor-chaperone complex, their contributions to health and disease, and their potential as therapeutic targets for the treatment of these diseases.

Download full-text

Full-text

Available from: Mario Galigniana, Jun 30, 2015
1 Follower
 · 
133 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The immunosuppressive ligand FK506 and the FK506-binding protein FKBP52 are stimulatory to glucocorticoid receptor (GR) activity. Here, we explore the underlying mechanism by comparing GR activity and phosphorylation status in response to FK506 and the novel nonimmunosuppressive ligand timcodar (VX-853) and in the presence and absence of FKBP52 and the closely related protein FKBP51. Using mouse embryonic fibroblast cells (MEFs) deficient knockout (KO) in FKBP51 or FKBP52, we show decreased GR activity at endogenous genes in 52KO cells, but increased activity in 51KO cells. In 52KO cells, elevated phosphorylation occurred at inhibitory serine 212 and decreased phosphorylation at the stimulatory S220 residue. In contrast, 51KO cells showed increased GR phosphorylation at the stimulatory residues S220 and S234. In wild-type (WT) MEF cells, timcodar, like FK506, potentiated dexamethasone-induced GR transcriptional activity at two endogenous genes. Using 52KO and 51KO MEF cells, FK506 potentiated GR activity in 51KO cells but could not do so in 52KO cells, suggesting FKBP52 as the major target of FK506 action. Like FK506, timcodar potentiated GR in 51KO cells, but it also increased GR activity in 52KO cells. Knock-down of FKBP51 in the 52KO cells showed that the latter effect of timcodar required FKBP51. Thus, timcodar appears to have a dual specificity for FKBP51 and FKBP52. This work demonstrates phosphorylation as an important mechanism in FKBP control of GR and identifies the first nonimmunosuppressive macrolide capable of targeting GR action.
    12/2014; 2(6). DOI:10.1002/prp2.76
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: MJC13 is a novel molecule that has potential application as a treatment of hormone refractory prostate cancer (HRPC). The purpose of this work was to develop a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for quantification of MJC13. Itraconazole was used as internal standard (IS). Acetonitrile was used to extract MJC13 from rat plasma and urine samples. A LC system equipped with a Waters XTerra MS C18 column (125Å, 3.5 µm, 4.6 x 150 mm) was used for chromatographic separation with water-0.2 % formic acid in acetonitrile as mobile phase. The API 3200 QTRAP triple quadrupole mass spectrometer was used for chromatographic analysis by multiple reaction monitoring (MRM) at positive mode with the transitions m/z 272→m/z 162 for MJC13, and m/z 705→m/z 392 for IS. The retention times for MJC13 and IS were 4.98 min and 4.42 min, respectively. The standard curves of MJC13 in solution, rat plasma, and rat urine were linear in the concentration range of 1 – 1000, 1 – 1000 and 1 – 200 ng/mL, respectively. The intra- and inter-day accuracy (relative error) ranged from 1.99 – 4.20% and 1.83 – 4.39%, respectively. The intra- and inter-day precision (coefficient of variation) ranged from 2.27 – 3.88% and 2.80 – 4.79%, respectively. The extraction recovery rates of rat plasma and urine samples were 95.3% and 96.2%, respectively. No measurable matrix effect interfered with MJC13 identification and quantification in rat plasma and urine. In summary, a rapid, specific, sensitive, and reproducible LC-MS/MS method was developed and validated to quantify MJC13 in solution, rat plasma, and rat urine.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Glucocorticoids play an important role in adipogenesis via the glucocorticoid receptor (GR) that forms a heterocomplex with Hsp90•Hsp70 and one high molecular weight immunophilin FKBP51 or FKBP52. When 3T3-L1 preadipocytes are induced to differentiate, FKBP51 expression progressively increases, whereas FKBP52 decreases, and Hsp90, Hsp70, p23 and Cyp40 remain unchanged. Interestingly, FKBP51 rapidly translocates from mitochondria to the nucleus where it is retained upon its interaction with chromatin and the nuclear matrix. FKBP51 nuclear localization is transient, after 48 h it cycles back to mitochondria. Importantly, this dynamic FKBP51 mitochondrial-nuclear shuttling depends on PKA signaling, since its inhibition by PKI or knock-down of PKA-cα by siRNA, abrogated FKBP51 nuclear translocation induced by IBMX. In addition, FKBP51 electrophoretic pattern of migration is altered by treatment of cells with PKI or knock-down of PKA-cα suggesting that FKBP51 is a PKA substrate. In preadipocytes, FKBP51 co-localizes with PKA-cα in mitochondria. When adipogenesis is triggered, PKA-cα also moves to the nucleus co-localizing with FKBP51 mainly in the nuclear lamina. Moreover, FKBP51 and GR interaction increases when preadipocytes are induced to differentiate. GR transcriptional capacity is reduced when cells are incubated in the presence of IBMX, forskolin or dibutiryl-cAMP, compounds that induced FKBP51 nuclear translocation, but not by an specific activator of EPAC. FKBP51 knock-down facilitates while ectopic expression of FKBP51 blocks adipogenesis. These findings indicate that the dynamic mitochondrial-nuclear shuttling of FKBP51 regulated by PKA may be key in fine tuning the transcriptional control of GR-target genes required for the acquisition of adipocyte phenotype.
    Journal of Cell Science 10/2013; 126(23). DOI:10.1242/jcs.125799 · 5.33 Impact Factor